Jorizzo Joseph L, Carney Patrick S, Ko William T, Robins Perry, Weinkle Susan H, Werschler Wm Philip
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Cutis. 2004 Dec;74(6 Suppl):18-23.
Several formulations and concentrations of topical fluorouracil have received US Food and Drug Administration (FDA) approval for the treatment of actinic keratosis (AK). The most commonly used are the fluorouracil 5% and 0.5% creams. In clinical trials, these formulations have demonstrated a marked ability to partially and completely eradicate AK lesions. Application site irritation, erythema, and burning are common side effects of both formulations, but comparative data suggest that the fluorouracil 0.5% cream is more cost-effective and may be safer, more tolerable, and as efficacious as fluorouracil 5% cream.
几种局部用氟尿嘧啶的制剂和浓度已获得美国食品药品监督管理局(FDA)批准用于治疗光化性角化病(AK)。最常用的是5%和0.5%的氟尿嘧啶乳膏。在临床试验中,这些制剂已显示出显著的部分或完全根除AK病变的能力。两种制剂常见的副作用都是用药部位刺激、红斑和烧灼感,但比较数据表明,0.5%的氟尿嘧啶乳膏性价比更高,可能更安全、更耐受,且与5%的氟尿嘧啶乳膏疗效相当。